Literature DB >> 29417299

First international TNBC conference meeting report.

Padmashree Rida1,2, Angela Ogden1, Ian O Ellis3, Zsuzsanna Varga4, Antonio C Wolff5, Tiffany A Traina6,7, Christos Hatzis8, Julie R Palmer9, Christine B Ambrosone10, Brian D Lehmann11, Rita Nanda12, Valerie Montgomery Rice13, Otis W Brawley14, Mylin A Torres15,16, Emad Rakha3, Ritu Aneja17.   

Abstract

Recently, Georgia State University's Centennial Hall was the premier location for the 2017 International Conference on Triple Negative Breast Cancer (TNBC): Illuminating Actionable Biology, which was held from Sept. 18 to 20, 2017, in Atlanta, USA. The conference featured a stellar line-up of domestic and international speakers and diverse participants including TNBC survivors, luminaries in breast cancer research, medical students and fellows, clinicians, translational researchers, epidemiologists, biostatisticians, bioinformaticians, and representatives from the industry. This report distills the burning questions that spiked the event and summarizes key themes, findings, unique opportunities and future directions that emerged from this confluence of thought leaders.

Entities:  

Keywords:  Immunotherapy; Molecular subtypes; Racial disparities; Targeted drugs; Triple negative breast cancer

Mesh：

Substances：

Year:  2018        PMID： 29417299      PMCID： PMC5955852          DOI： 10.1007/s10549-018-4692-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  29 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  What are health disparities and health equity? We need to be clear.

Authors:  Paula Braveman
Journal:  Public Health Rep       Date:  2014 Jan-Feb       Impact factor: 2.792

3.  Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.

Authors:  Uma Krishnamurti; Ceyda Sonmez Wetherilt; Jing Yang; Limin Peng; Xiaoxian Li
Journal:  Hum Pathol       Date:  2017-01-30       Impact factor: 3.466

Review 4.  Health Disparities and Triple-Negative Breast Cancer in African American Women: A Review.

Authors:  Lisa A Newman; Linda M Kaljee
Journal:  JAMA Surg       Date:  2017-05-01       Impact factor: 14.766

Review 5.  Triple-negative breast cancer in African-American women: disparities versus biology.

Authors:  Eric C Dietze; Christopher Sistrunk; Gustavo Miranda-Carboni; Ruth O'Regan; Victoria L Seewaldt
Journal:  Nat Rev Cancer       Date:  2015-02-12       Impact factor: 60.716

6.  Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.

Authors:  Matt I Gross; Susan D Demo; Jennifer B Dennison; Lijing Chen; Tania Chernov-Rogan; Bindu Goyal; Julie R Janes; Guy J Laidig; Evan R Lewis; Jim Li; Andrew L Mackinnon; Francesco Parlati; Mirna L M Rodriguez; Peter J Shwonek; Eric B Sjogren; Timothy F Stanton; Taotao Wang; Jinfu Yang; Frances Zhao; Mark K Bennett
Journal:  Mol Cancer Ther       Date:  2014-02-12       Impact factor: 6.261

7.  Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.

Authors:  Hiroko Masuda; Keith A Baggerly; Ying Wang; Ya Zhang; Ana Maria Gonzalez-Angulo; Funda Meric-Bernstam; Vicente Valero; Brian D Lehmann; Jennifer A Pietenpol; Gabriel N Hortobagyi; W Fraser Symmans; Naoto T Ueno
Journal:  Clin Cancer Res       Date:  2013-08-15       Impact factor: 12.531

Review 8.  Triple-negative breast cancer: new perspectives for novel therapies.

Authors:  Yashin A Mahamodhossen; Wei Liu; Zhou Rong-Rong
Journal:  Med Oncol       Date:  2013-07-04       Impact factor: 3.738

9.  Expression of Tumor-Related Macrophages and Cytokines After Surgery of Triple-Negative Breast Cancer Patients and its Implications.

Authors:  Jianguo Wang; Hongwu Chen; Xingwu Chen; Hui Lin
Journal:  Med Sci Monit       Date:  2016-01-11

10.  Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.

Authors:  Tingting Jiang; Weiwei Shi; Vikram B Wali; Lőrinc S Pongor; Charles Li; Rosanna Lau; Balázs Győrffy; Richard P Lifton; William F Symmans; Lajos Pusztai; Christos Hatzis
Journal:  PLoS Med       Date:  2016-12-13       Impact factor: 11.069
View more
  2 in total

1.  Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping.

Authors:  Carolin Hartung; Martin Porsch; Kathrin Stückrath; Sandy Kaufhold; Martin S Staege; Volker Hanf; Tilmann Lantzsch; Christoph Uleer; Susanne Peschel; Jutta John; Marleen Pöhler; Edith Weigert; Jörg Buchmann; Karl-Friedrich Bürrig; Kathleen Schüler; Daniel Bethmann; Ivo Große; Eva Johanna Kantelhardt; Christoph Thomssen; Martina Vetter
Journal:  Breast Care (Basel)       Date:  2021-10-19       Impact factor: 2.860

2.  LncRNA-HAGLR motivates triple negative breast cancer progression by regulation of WNT2 via sponging miR-335-3p.

Authors:  Liting Jin; Chenggang Luo; Xinhong Wu; Manxiu Li; Shun Wu; Yaojun Feng
Journal:  Aging (Albany NY)       Date:  2021-08-10       Impact factor: 5.682
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.